SCYNEXIS (SCYX)
(Real Time Quote from BATS)
$1.49 USD
-0.07 (-4.49%)
Updated Sep 23, 2024 03:16 PM ET
4-Sell of 5 4
D Value B Growth D Momentum C VGM
Price, Consensus and EPS Surprise
SCYX 1.49 -0.07(-4.49%)
Will SCYX be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for SCYX based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for SCYX
Verve Therapeutics (VERV) Soars 13.8%: Is Further Upside Left in the Stock?
PTC Therapeutics (PTCT) Surges 5.8%: Is This an Indication of Further Gains?
SCYX: What are Zacks experts saying now?
Zacks Private Portfolio Services
SCYNEXIS (SCYX) Skyrockets 134% Year to Date: Here's Why
Amylyx Pharmaceuticals, Inc. (AMLX) Surpasses Q2 Earnings and Revenue Estimates
Avalo Therapeutics, Inc. (AVTX) Reports Q2 Loss, Misses Revenue Estimates
Other News for SCYX
SCYNEXIS to Participate in H. C. Wainwright 26th Annual Global Investment Conference
Buy Rating Affirmed for SCYNEXIS Amid Antifungal Progress and Market Potential
SCYX Stock Earnings: SCYNEXIS Misses EPS, Misses Revenue for Q2 2024
Wall Street Analysts Are Bullish on Top Healthcare Picks
Scynexis: Q2 Earnings Snapshot